Healthcare provider profile · identity verified

Melvin Khaw, M.D.

Internal Medicine · ENCINO, CA · NPI 1487624045

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	341	99
Rosuvastatin Calcium	Rosuvastatin Calcium	208	58
Levothyroxine Sodium	Levothyroxine Sodium	190	55
Amlodipine Besylate	Amlodipine Besylate	175	45
Lisinopril	Lisinopril	126	35
Famotidine	Famotidine	119	39
Irbesartan	Irbesartan	100	27
Zolpidem Tartrate	Zolpidem Tartrate	98	23
Alprazolam	Alprazolam	96	31
Synthroid	Levothyroxine Sodium	88	20
Azithromycin	Azithromycin	87	73
Metoprolol Succinate	Metoprolol Succinate	80	22
Hydrochlorothiazide	Hydrochlorothiazide	79	22
Metformin Hcl	Metformin Hcl	75	22
Escitalopram Oxalate	Escitalopram Oxalate	74	22
Repatha Sureclick	Evolocumab	74	17
Gabapentin	Gabapentin	71	25
Trazodone Hcl	Trazodone Hcl	69	19
Tamsulosin Hcl	Tamsulosin Hcl	66	19
Olmesartan Medoxomil	Olmesartan Medoxomil	65	18
Sertraline Hcl	Sertraline Hcl	64	19
Montelukast Sodium	Montelukast Sodium	62	18
Pravastatin Sodium	Pravastatin Sodium	56	21
Alendronate Sodium	Alendronate Sodium	51	15
Eliquis	Apixaban	51	11
Allopurinol	Allopurinol	47	15
Valacyclovir	Valacyclovir Hcl	45	18
Lorazepam	Lorazepam	41	12
Omeprazole	Omeprazole	38	18
Sumatriptan Succinate	Sumatriptan Succinate	37	12
Mounjaro	Tirzepatide	35	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	25
Ipratropium Bromide	Ipratropium Bromide	31	11
Losartan Potassium	Losartan Potassium	31	suppressed
Ozempic	Semaglutide	31	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	31	28
Lagevrio (Eua)	Molnupiravir	30	27
Praluent Pen	Alirocumab	29	suppressed
Simvastatin	Simvastatin	29	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	28	13
Albuterol Sulfate Hfa	Albuterol Sulfate	27	13
Ezetimibe	Ezetimibe	25	suppressed
Finasteride	Finasteride	25	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	24	suppressed
Cefdinir	Cefdinir	23	19
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	19
Diazepam	Diazepam	21	suppressed
Prednisone	Prednisone	20	15
Zaleplon	Zaleplon	20	suppressed
Meloxicam	Meloxicam	19	suppressed
Ondansetron Odt	Ondansetron	19	16
Spironolactone	Spironolactone	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Valsartan	Valsartan	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Furosemide	Furosemide	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Icosapent Ethyl	Icosapent Ethyl	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Candesartan Cilexetil	Candesartan Cilexetil	13	suppressed
Carvedilol	Carvedilol	13	suppressed
Minoxidil	Minoxidil	13	suppressed
Naproxen	Naproxen	13	suppressed
Dexlansoprazole Dr	Dexlansoprazole	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error